During the past decade, Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 12 clinical trials were completed, i.e. on average, 92.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 11 clinical trials were completed. i.e. 1100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM" #1 sponsor was "R-Pharm International, LLC" with 3 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "Mene Research" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM" are "Rheumatoid Arthritis" (8 trials), "Arthritis, Rheumatoid" (2 trials), "Lupus Erythematosus, Systemic" (2 trials) and "Systemic Lupus Erythematosus" (2 trials). Many other conditions were trialed in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM" in a lesser frequency.

Most popular intervention types in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM" are "Drug" (14 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "GDC-0853" (2 trials), "Adalimumab" (1 trials), "Adalimumab 40mg q2w" (1 trials) and "Anti-TNF-alpha" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".